Jeffrey N Weitzel
Overview
Explore the profile of Jeffrey N Weitzel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
219
Citations
11124
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Mesa-Chavez F, Chavarri-Guerra Y, Aguilar-Y-Mendez D, Becerril-Gaitan A, Vaca-Cartagena B, Carrillo-Bedoya A, et al.
JCO Glob Oncol
. 2024 Apr;
10:e2300417.
PMID: 38635940
Purpose: Genetic cancer risk assessment (GCRA) provides pathogenic variant (PV) carriers with the invaluable opportunity to undertake timely cancer risk-reducing (RR) measures and initiate cascade testing (CT). This study describes...
12.
Barnes D, Tyrer J, Dennis J, Leslie G, Bolla M, Lush M, et al.
medRxiv
. 2024 Mar;
PMID: 38496424
Background: Nineteen genomic regions have been associated with high-grade serous ovarian cancer (HGSOC). We used data from the Ovarian Cancer Association Consortium (OCAC), Consortium of Investigators of Modifiers of (CIMBA),...
13.
Westbrook L, Miltenburg D, Souter V, Maisenbacher M, Howard K, Sha Y, et al.
Breast Cancer Res Treat
. 2023 Oct;
203(2):365-372.
PMID: 37861889
Purpose: Up to 10% of all breast cancers (BC) are attributed to inherited pathogenic variants (PV) in BC susceptibility genes; however, most carriers of PVs remain unidentified. Here, we sought...
14.
Stolarova L, Kleiblova P, Zemankova P, Stastna B, Janatova M, Soukupova J, et al.
Clin Cancer Res
. 2023 Jul;
29(16):3037-3050.
PMID: 37449874
Purpose: Germline pathogenic variants in CHEK2 confer moderately elevated breast cancer risk (odds ratio, OR ∼ 2.5), qualifying carriers for enhanced breast cancer screening. Besides pathogenic variants, dozens of missense...
15.
Hu C, Nagaraj A, Shimelis H, Montalban G, Lee K, Huang H, et al.
Cancer Res
. 2023 May;
83(15):2557-2571.
PMID: 37253112
Significance: Functional analysis of the impact of a large number of missense variants on RAD51C function provides insight into RAD51C activity and information for classification of the cancer relevance of...
16.
Ding Y, Song H, Adamson A, Schmolze D, Hu D, Huntsman S, et al.
Cancer Res
. 2023 May;
83(15):2600-2613.
PMID: 37145128
Significance: Comprehensive characterization of genomic and transcriptomic alterations in breast tumors from Hispanic/Latina patients reveals distinct genetic alterations and signatures, demonstrating the importance of inclusive studies to ensure equitable care...
17.
OMahony D, Ramus S, Southey M, Meagher N, Hadjisavvas A, John E, et al.
Br J Cancer
. 2023 Apr;
128(12):2283-2294.
PMID: 37076566
Background: The distribution of ovarian tumour characteristics differs between germline BRCA1 and BRCA2 pathogenic variant carriers and non-carriers. In this study, we assessed the utility of ovarian tumour characteristics as...
18.
Goldring G, Trotter C, Meltzer J, Souter V, Pais L, DiNonno W, et al.
Obstet Gynecol
. 2023 Mar;
141(4):791-800.
PMID: 36897127
Objective: To evaluate the incidence and clinical outcomes of cell-free DNA results suspicious for maternal malignancy on prenatal cell-free DNA screening with single-nucleotide polymorphism (SNP)-based technology. Methods: This retrospective cohort...
19.
Tshiaba P, Ratman D, Sun J, Tunstall T, Levy B, Shah P, et al.
JCO Precis Oncol
. 2023 Feb;
7:e2200447.
PMID: 36809055
Purpose: To develop and validate a cross-ancestry integrated risk score (caIRS) that combines a cross-ancestry polygenic risk score (caPRS) with a clinical estimator for breast cancer (BC) risk. We hypothesized...
20.
Nierenberg J, Adamson A, Hu D, Huntsman S, Patrick C, Li M, et al.
medRxiv
. 2023 Feb;
PMID: 36747679
Introduction: Breast cancer (BC) is one of the most common cancers globally. Genetic testing can facilitate screening and risk-reducing recommendations, and inform use of targeted treatments. However, genes included in...